Academic Journals Database
Disseminating quality controlled scientific knowledge

Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation

ADD TO MY LIST
 
Author(s): Arroyo Patricia | Perez Ruth | Feijoo Maria | Hernandez Miguel

Journal: Journal of Cancer Research and Therapeutics
ISSN 0973-1482

Volume: 6;
Issue: 4;
Start page: 573;
Date: 2010;
Original page

Keywords: Anthracycline | chemotherapy | cost | dexrazoxane | extravasation

ABSTRACT
A 75-year-old man diagnosed with lower esophageal adenocarcinoma suffered from epirubicin extravasation during the second cycle of neoadjuvant chemotherapy with epirubicin and oxaliplatin. A full recovery was achieved after treatment with dexrazoxane (Cardioxane® ). This is the first time in our hospital that extravasation of an anthracycline has been treated with dexrazoxane. We used Cardioxane® , approved for the prevention of anthracycline-induced cardiotoxicity, while Savene® is indicated for the treatment of anthracycline extravasation. The treatment was effective, and the selection of Cardioxane® (seven-fold cheaper than Savene® ) yielded a cost saving. Consequently, Cardioxane® has been included in our guidelines for anthracycline extravasation.
Affiliate Program      Why do you need a reservation system?